<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246739</url>
  </required_header>
  <id_info>
    <org_study_id>2010/297</org_study_id>
    <nct_id>NCT01246739</nct_id>
  </id_info>
  <brief_title>Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome</brief_title>
  <acronym>AUSC</acronym>
  <official_title>Adrenalectomy Versus Follow-up in Patients With Mild Hypercortisolism: a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incidental findings of adrenal tumours,&quot;incidentalomas&quot;, occur in 1-5 % in the general&#xD;
      population and 10-25 % of these patients will exhibit biochemical mild hypercortisolism.&#xD;
      Although the patients do not have clinical signs of classical Cushing's syndrome, they have&#xD;
      an increased risk for hypertension, dyslipidemia, diabetes mellitus, osteoporosis and&#xD;
      obesity.&#xD;
&#xD;
      The hypothesis of the study is, that surgery of the adrenal adenoma responsible for the&#xD;
      increased secretion of cortisol, will in part cure or ameliorate the metabolic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenal incidentalomas, adrenal tumours detected without symptoms and signs of hormonal&#xD;
      hypersecretion or malignancy, are common. Depending on modality (MRI, CT. Ultrasonography)&#xD;
      adrenal tumours occur in approximately 1-5% of the population. In about 10% of patients, the&#xD;
      tumours are bilateral. At autopsy studies adrenal tumours occur in 1% of patients under the&#xD;
      age of 30, but in approximately 7% of patients older than 70 years. Investigation of the&#xD;
      adrenal tumours focus on to exclude malignancy (which is uncommon), and an increased&#xD;
      secretion of hormones (adrenaline, aldosterone, cortisol), so-called functional tumours.&#xD;
      However, most often adrenal incidentalomas are non-functional. The most common functional&#xD;
      disorder is increased secretion of cortisol, and then usually without clinical stigmata,&#xD;
      known as subclinical Cushing's syndrome (or mild hypercortisolism). Clinical stigmata,&#xD;
      Cushing's syndrome, is empirically associated with elevated levels of urinary cortisol.&#xD;
&#xD;
      Subclinical Cushing's syndrome occurs in 10-25% of patients with adrenal incidentalomas. The&#xD;
      incidence has been estimated at 0.8 / 1,000 inhabitants, making it a common disease.&#xD;
&#xD;
      Diagnosis is based to detect an autonomous release of cortisol from the adrenal gland (a&#xD;
      disorder of the so-called hypothalamic-pituitary-adrenal axis).&#xD;
&#xD;
      Fundamental to the diagnosis is that the secretion of cortisol is not inhibited &lt;50 nmol / L&#xD;
      at 8.00, after an overnight test with 1 mg of oral dexamethasone.&#xD;
&#xD;
      In addition, at least one of the following criteria for disturbance of the&#xD;
      hypothalamic-pituitary-adrenal axis is suggested to be present:&#xD;
&#xD;
        -  attenuated or abolished circadian rhythm of cortisol&#xD;
&#xD;
        -  ACTH in the low normal range or supressed&#xD;
&#xD;
        -  DHEAS low or supressed (age dependent)&#xD;
&#xD;
      Numerous studies have shown that high blood pressure, diabetes, impaired glucose tolerance,&#xD;
      and unfavourable lipid profile, is common in patients with subclinical Cushing's syndrome,&#xD;
      and basically do not differ from patients with overt Cushing's syndrome. At follow-up of&#xD;
      patients with adrenal incidentalomas, some patients exhibit intermittent mild hypersecretion&#xD;
      of cortisol, others develop overt Cushing's syndrome (unusual) and still some patients with&#xD;
      initially normal hypothalamic-pituitary-adrenal axis, develop a subclinical Cushing's&#xD;
      syndrome.&#xD;
&#xD;
      The aim of this study is to investigate if adrenalectomy for subclinical Cushing's syndrome&#xD;
      (mild hypercortisolism without clinical signs), result in an improvement in cardiovascular&#xD;
      risk factors, cardiac function, and arteriosclerosis compared to follow-up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of blood pressure as assessed by 24 hours blood pressure measurement</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Blood pressure assessed by 24 hours measurement is considered to be improved if at least one of the following outcomes has occurred, and is sustained, during 2 years of follow-up:&#xD;
Normalization of hypertension without medical treatment&#xD;
Unchanged or decreased blood pressure in patients with hypertension if the number or dose of the patient's antihypertensive drug (s) has been reduced&#xD;
Unchanged normal blood pressure in patients who were normotensive at the time of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of diabetes mellitus</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Normalization of diabetes mellitus according to the criteria of the World Health Organization and assessed by oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased body mass index (BMI) to &lt; 30</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Standard assessment of BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Bone density assessed with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Triglyceride and cholesterol changes of whole serum and of the lipoprotein classes; low-density-lipoprotein (LDL), very-low-density-lipoprotein (VLDL) and high-density-lipoprotein (HDL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>At two years post intervention</time_frame>
    <description>Cardiac function assessed by echocardiography; left ventricular ejection fraction (EF), left ventricular end-diastolic diameter (LVDD), left ventricular mass index (LVMI), ratio between mitral peak velocity flow of the early filling wave and the atrial wave (E/A ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Mini Mental State Examination (MMSE) for cognitive function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by SF 36</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Quality of Life assessed by the generic instrument short form 36 (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atherosclerosis</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Carotid ultrasound/duplex scans with evaluation of intimal thickness and plaques.&#xD;
Blood pressure measurement for ankle index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenal cortical insufficiency</measure>
    <time_frame>At two years after intervention</time_frame>
    <description>Rate of patients with postoperative adrenal cortical insufficiency in patients operated due to subclinical Cushings syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adrenal Tumour With Mild Hypercortisolism</condition>
  <arm_group>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adrenalectomy</intervention_name>
    <description>Adrenalectomy (open or laparoscopic)</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adrenal tumour with biochemical mild hypercortisolism defined as pathological&#xD;
             dexamethasone suppression test (cortisol &gt; 50 nmol/L at 8.00 am after 1 mg&#xD;
             dexamethasone at 10 pm, plus one of the following criteria&#xD;
&#xD;
               -  Low or suppressed adrenocorticotropic hormone (ACTH)&#xD;
&#xD;
               -  Low or suppressed dehydroepiandrosterone (DHEA)&#xD;
&#xD;
               -  No or pathological circadian rhythm of cortisol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Increased levels of 24 hours urinary excretion of cortisol&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Inability to understand information or to comply with scheduled follow-up&#xD;
&#xD;
          -  Mild hypercortisolism with bilateral adrenal tumours, without a gradient&#xD;
             (lateralization on venous sampling)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Skåne University Hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders OJ Bergenfelz, MD, PhD</last_name>
    <phone>+4646172086</phone>
    <email>anders.bergenfelz@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik Nordenström, MD, PhD</last_name>
    <phone>+4646172305</phone>
    <email>erik.nordenstrom@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Århus University Hospital</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Poulsen, MD, PhD,DMSc</last_name>
      <phone>+4578462008</phone>
      <email>logstrup.@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette Heie, MD</last_name>
      <phone>+4797647525</phone>
      <email>anette.heie@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Grethe Åström Ueland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hrafnkell B Thordarson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Turid Aas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eystein S Husebye, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oskar Ragnarsson, MD, PhD</last_name>
      <phone>+46707292228</phone>
      <email>oskar.ragnarsson@medic.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital-Lund, Department of Surgery</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders OJ Bergenfelz, PhD</last_name>
      <phone>+46703772086</phone>
      <email>anders.bergenfelz@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Erik Nordenström, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Almqvist, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild hypercortisolism</keyword>
  <keyword>adrenal tumour</keyword>
  <keyword>surgical procedures, elective</keyword>
  <keyword>indication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

